At KBP we are consistently reminded that patient care is the end goal of what we do daily.
Our discovery team is highly experienced in identifying new compounds with the potential to positively impact the lives of patients. The close interactions of the integrated discovery and development teams have enabled us to create a deep pipeline with multiple clinical and pre-clinical compounds. We are actively seeking partnerships in each of our core areas of interest, both to access capabilities that will further the advancement of our existing pipeline as well as to bring in new pre-clinical and clinical stage programs into our pipeline.
The major organ research group is focused on the maintenance and postponement of disease progression of three primary organ systems – lung, heart, and kidney – and is capable of assessing a drug’s activity and active mechanism in both in vitro and in vivo models.
The antimicrobial group leverages a proprietary microbial bank comprised of 20,000+ clinically-isolated strains, including anaerobic bacteria and fungi, to evaluate drug candidates effectively. We are actively seeking potential partners with novel targets to collaborate with on the identification of new drug candidates.
The immunology group conducts research on the roles of T- and B-cells in a number of diseases including rheumatoid arthritis, hyperuricemia, and idiopathic pulmonary fibrosis.
Our laser-focus on these three therapeutic areas provides powerful and unique insights on the underlying physiological and pathological processes that drive disease, opening up new avenues to tackle specific targets. Our researchers use their expertise to locate these new directions and exploit them, resulting in innovative therapies for a wide variety of illnesses.